Review ENBREL’s clinical study designs and results in treating patients with psoriatic arthritis (PsA)
Evaluation of ENBREL and methotrexate (MTX) as monotherapies and as combination therapy in psoriatic arthritis
The Study of Etanercept and Methotrexate (SEAM) PsA Study was a 48-week, multicenter, randomized, double-blind controlled study of 851 subjects with active PsA naïve to biologics and with no prior use of MTX for the treatment of PsA. Eligible patients were randomized to receive ENBREL + MTX combination therapy (n=283), ENBREL monotherapy (n=284), or MTX monotherapy (n=284).1
*Rescue option = ENBREL 50 mg per week + MTX 20 mg per week if inadequate response (<20% improvement in TJC and SJC from baseline) at or after 24 weeks.1
| Demographic/ Characteristics |
MTX Monotherapy (n=284) | ENBREL Monotherapy (n=284) | ENBREL + MTX (n=283) |
|---|---|---|---|
| Mean age in years (SD) | 48.7 (13.1) | 48.5 (13.5) | 48.1 (12.7) |
| % female | 56.3% | 46.8% | 49.1% |
| Mean years disease duration (SD) | 3.6 (6.8) | 3.1 (6.0) | 3.0 (6.0) |
| Mean years mTSS (SD) | 2.76 (0.12) | 2.97 (0.13) | 2.70 (0.12) |
| % dactylitis (LDI) | 34.5% | 33.8% | 31.8% |
| % enthesitis (SPARCC) | 67.3% | 66.5% | 69.3% |
| % nail disease (mNAPSI) | 65.1% | 72.5% | 69.6% |
| Mean tender joint count (SD) | 20.9 (15.0) | 18.8 (14.5) | 20.0 (15.3) |
| Mean swollen joint count (SD) | 12.9 (9.9) | 11.5 (9.6) | 11.2 (9.1) |
| Mean % BSA | 12.7% | 10.8% | 10.7% |
| Mean sPGA (SD) | 2.6% (1.1) | 2.6% (1.0) | 2.5% (1.0) |
Patients taking ENBREL with or without MTX experienced significant improvements in joint symptoms1
Patients on ENBREL monotherapy and ENBREL + MTX experienced similar ACR 50 and ACR 70 responses at Week 241
Patients on ENBREL with or without MTX did not experience progression of joint damage2
In the SEAM-PsA study, ENBREL monotherapy and ENBREL + MTX resulted in joint pain reduction3
ENBREL with or without MTX resulted in joint pain reduction through Week 483
Mean change from baseline in patient assessment of pain (VAS) through Week 483
Patients on ENBREL monotherapy experienced improvements in sPGA1
8 out of 10 patients on ENBREL with psoriasis BSA ≥10% achieved sPGA of clear to almost clear at Week 241
~7 out of 10 patients on ENBREL achieved BSA improvement at Week 241
MDA measures the state of PsA disease activity and defines a target for treatment. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommends MDA as a potential treatment target, as it encompasses most aspects of the disease and there is no clear definition of remission.4
Patients taking ENBREL with or without MTX experienced significant improvements in MDA response rates
*P=0.005 vs MTX (adjusted).6
For ACR 20 and MDA at Week 24, formal comparisons were tested using Bonferroni-based gatekeeping chain procedure to control
the type 1 error rate at 0.05 and nonresponder imputation was used for missing data. For other endpoints, P values are nominal (not
adjusted for multiplicity) and data were analyzed as observed.1
Patients taking ENBREL with or without MTX experienced improvements in dactylitis and enthesitis6
Patients taking ENBREL with or without MTX experienced improvements in nail disease (mNAPSI)6
ACR, American College of Rheumatology; ACR 20/50/70, American College of Rheumatology (20/50/70) percent response; BSA, body surface area; HAQ, Health Assessment Questionnaire; LDI, Leeds Dactylitis Index; MDA, minimal disease activity; mNAPSI, modified Nail Psoriasis Index; mTSS, modified total Sharp score; PASI, Psoriasis Area and Severity Index; SD, standard deviation; SJC, swollen joint count; SPARCC, Spondyloarthritis Research Consortium of Canada; sPGA, static Physician's Global Assessment; TJC, tender joint count; VAS, visual analog scale.
Evaluation of ENBREL in PsA, including joint, skin, and pain results
The PsA Pivotal Study was a 24-week, multicenter, double-blind study of 205 patients with active PsA who had a mean duration of arthritic disease of 9.1 years and mean duration of plaque psoriasis of 19 years (with a qualifying target skin lesion). Patients were randomized to receive ENBREL 25 mg biweekly (BIW, n=101) or placebo BIW (n=104). The 24-week, double-blind period was followed by a maintenance period of up to 24 weeks to allow all patients to complete the double-blind study. At Week 48, the maintenance period was followed by an open-label extension (OLE, n=168). Concomitant use of MTX, NSAID, corticosteroids, and topical therapies were permitted in the OLE at the discretion of the investigator.7
*Patients were stratified by MTX use at baseline for equal distribution between treatment arms. Patients on MTX therapy at enrollment (stable for 2 months) could continue at a stable dose of 25 mg/week MTX.8
†Stable use of corticosteroids and/or NSAIDs allowed.8
‡81 from placebo group; 87 from ENBREL group.7
ENBREL significantly inhibited joint damage progression
86% of patients on ENBREL showed no radiographic progression at 2 years vs 63% in placebo arm9
*Per protocol, in order to compare the radiographic images at Year 2 with images from baseline, 6 months, and 1 year, all images were reread. Because of the known variability in evaluation of radiographic images in psoriatic arthritis, all radiographs were reread, blinded to patient and time point, by 2 of 4 physicians. Radiographic scores were reported as an average from the 2 readers. Thus, the Year 2 scoring of the radiographic images is considered a new reading of the Year 1 time point.
†An mTSS, which included distal interphalangeal joints, was used. All radiographic data are based on the radiographic intent-to-treat (ITT) analysis, defined as all randomly assigned patients with acceptable baseline and post-baseline radiographs. Linear extrapolation methodology was used.
‡Patients were stratified by concomitant MTX.
ENBREL helps patients achieve clearer skin7,8
~7 out of 10 ENBREL patients had an sPGA of clear or almost clear at Week 2410†
*Patients had plaque psoriasis involvement ≥3% BSA at baseline.8
†Assessment was determined on a 0 to 5 (clear to severe psoriasis) scale.8
‡Patients were stratified by concomitant MTX.8
ENBREL helps patients feel less pain (based on VAS)
~50% difference in patient pain assessment with ENBREL vs placebo8
*Patients were stratified by concomitant MTX.
ENBREL improved patients’ physical function
2x more patients achieved HAQ ≤0.5 with ENBREL12
*HAQ score of ≤0.5 is consistent with the score of the general population.13
†Patients were stratified by concomitant MTX.8
ITT, intent-to-treat; NSAIDs, non-steroidal anti-inflammatory drugs; PASI 50/75, 50% and 75% reduction in the PASI scores.
Prescription Enbrel® (etanercept) is administered by injection.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
SERIOUS INFECTIONS
Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.
MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.
In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.
Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.
Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.
Pediatric Patients
In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin's and non-Hodgkin's lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.
NEUROLOGIC REACTIONS
Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.
CONGESTIVE HEART FAILURE
Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.
HEMATOLOGIC REACTIONS
Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.
HEPATITIS B REACTIVATION
Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients.
ALLERGIC REACTIONS
Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.
IMMUNIZATIONS
Live vaccines should not be administered to patients on ENBREL. Pediatric patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, temporarily discontinue ENBREL and consider prophylactic treatment with Varicella Zoster Immune Globulin.
AUTOIMMUNITY
Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.
USE IN GRANULOMATOSIS WITH POLYANGIITIS PATIENTS
The use of ENBREL in patients with granulomatosis with polyangiitis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.
MODERATE TO SEVERE ALCOHOLIC HEPATITIS
Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.
ADVERSE REACTIONS
The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.
In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.
DRUG INTERACTIONS
The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.
Please see Prescribing Information and Medication Guide.
INDICATIONS
ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.
ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without MTX.
ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.
Prescription Enbrel® (etanercept) is administered by injection.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
SERIOUS INFECTIONS
Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated
Patients treated with ENBREL are at increased risk for developing serious infections that may lead to
References:
